North America & Europe Artificial Pancreas Systems Market Continues To Expand Rapidly With Growing Diabetes Cases And Continuous R&D Efforts

Artificial Pancreas Systems have come a long way since their inception and many advancements have been made. In the past artificial pancreas was used primarily to treat diabetes. However, today there are many other conditions that mimic or even correct diabetes and this includes chronic renal failure disease (CRF).

CRF is caused by a shortage in the body's natural ability to produce insulin or sugar. The primary factor aiding the demand for artificial pancreas systems is rapidly increasing cases of diabetes. As per the International Diabetes Foundation (IDF), in 2019, around 59 million adults aged 20-79 years were diabetic in Europe. According to the American Diabetes Association (ADA), in 2018, around 34.2 million U.S. citizens or around 10.5% of the population had diabetes. Thus, such high prevalence can stimulate growth of the North America & Europe artificial pancreas systems market.

Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/3348

Since there is a high prevalence of diabetes in both North America and Europe, research and development activities have increased over the years. These activities are focused on developing novel diabetes therapies, medications, and supportive systems. With growing focus on R&D activities from both private and government entities, North America & Europe artificial pancreas systems market is likely to bolster in the near future. Recently, in September 2020, Medtronic received the U.S. Food and Drug Administration (FDA) approval for its next-generation hybrid closed-loop insulin delivery system MiniMed 770G system for children aged 2 to 6 years with type 1 diabetes.

LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!

Buy Now with Discount for Premium Report (Flat US $ 2000 Off) : https://www.coherentmarketinsights.com/promo/buynow/3348

Automated systems designed for diabetes, mainly type 1, are basically automated systems designed to help people with uncontrolled diabetes, mainly type 1, control their blood sugar levels by manually administering insulin to them. Today, however, available artificial pancreas systems can only deliver single hormone glucose. As far as the regional footprint is concerned, North America seems to be gaining significant traction in the North America & Europe artificial pancreas systems market. This is due to growing awareness regarding diabetes and advancements in research and technology in the region. On the contrary, Europe is registering a positive outlook due to higher healthcare expenditure and high patient awareness levels.

There are several other benefits that artificial pancreas systems offer. These include the ability to treat different types of diseases and illnesses, such as adult-onset diabetes, and renal diseases. It can also treat complications such as hypoglycemia and hyperglycemia. It can even improve the effectiveness of other types of medication, such as beta-blockers and anti-cholesterol medications. Regardless of the advantageous factors, there certain aspects that can pose severe challenges. For instance, concerns regarding the quality of insulin in some parts of the world can limit market growth. Furthermore, alteration in efficiency of sensors caused by fibrosis since they are placed subcutaneously can impede growth of the North America & Europe artificial pancreas systems market.

305 Broadway
7th Floor, New York City,
NY 10007, United States,
Telephone - +1-646-568-7751
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.